A Study of Neoadjuvant Hormone Therapy in Patient With Advanced Prostate Cancer Undergoing Radical Prostatectomy.

Advanced Prostate Cancer Clinical Trial

Official title:

A Multi-centre, Single-arm, Prospective Study to Assess Efficacy and Safety of Neoadjuvant Hormone Therapy Using Zoladex (Goserelin) and Casodex (Bicalutamide) in Patients With Advanced Prostate Cancer Undergoing Radical Prostatectomy.

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03971110
• Other study ID #: D8664C09827
• Status: Terminated
• Phase: Phase 4
• Start date: January 28, 2021
• Est. completion date: November 9, 2022

Study information

• Verified date: December 2022
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is A Multi-centre, Single-arm, Prospective, Interventional Study to Assess Efficacy and Safety of Neoadjuvant Hormone Therapy using Zoladex (Goserelin) and Casodex (Bicalutamide) in Patients with Advanced Prostate Cancer Undergoing Radical Prostatectomy, to assess the efficacy by resectability rate of neoadjuvant hormone therapy (NHT) in subjects with advanced prostate cancer.

Description:

Neoadjuvant hormonal treatment (NHT) for clinically localised prostate cancer consists of complete androgen blockade (CAB) preceding either radiotherapy or surgery. The rational for this approach is based on the assumption that NHT will reduce both the tumour and normal prostatic tissue volume, and induce cancer regression by the mechanism of apoptosis [1].

Most randomized clinical trials show that NHT reduces the incidence of positive surgical margins after radical prostatectomy and apparently determines tumour downstaging, however no advantage has been documented in terms of biochemical disease progression [for example, time to prostate specific antigen (PSA) increase] between treated and untreated patients [2-8]. Because of relatively low biological aggressiveness of prostatic carcinoma, many patients will need to be followed for a considerable time before drawing significant conclusions on the effects of NHT on survival [2,4,7,10]. A large sample of 393 radical prostatectomy specimens were evaluated in 3 treatment groups, which were immediate surgery, 12 weeks of NHT (Zoladex and Casodex), and 24 weeks of NHT. Patients included clinical stage B (T2a and T2b) and stage C (T3a and T3b). Systemic hormonal treatment, whether 12 weeks or 24 weeks of NHT, is able to "downstage" the primary tumour and decrease the positive margin rate before definitive localised treatment [11].

Currently treatment of patients with oligometastatic prostate cancer is undergoing dramatic changes [12]. The local treatment of the primary tumour might provide a survival benefit to men with metastatic and lymph node-positive disease. Similar observations have been made in treatment of metastatic lesions with life-prolonging, rather than palliative intent [13-17].

This study is proposed primarily to observe the efficacy and safety of 24-week NHT (Zoladex and Casodex) in patients with locally advanced or oligometastatic prostate cancer. Progression status and survival will be followed-up for up to 2 years after NHT.

This is a multi-centre, single-arm and prospective study to explore the efficacy and safety of neoadjuvant hormone therapy (NHT) for advanced prostate cancer patients undergoing radical prostatectomy (RP). A total of 104 subjects with locally advanced and oligometastatic prostate cancer at clinical stage of T3 and T4 will be enrolled at almost 20 centres in China.

The eligible subjects will receive Casodex 50 mg orally per day in combination with Zoladex 10.8 mg implant subcutaneously every 12 weeks as neoadjuvant therapy for 24 weeks, and then will be assessed for resectability of the primary tumour. The subjects will undergo a RP [RALP (robot-assisted laparoscopic prostatectomy), laparoscopic RP or RRP (radical retropubic prostatectomy)] plus eLND thereafter if the primary tumour is assessed as resectable. Surgical margin status and involvement of bilateral pelvic lymph nodes will be evaluated. Subjects will be prescribed post-surgical treatment such as continuous ADT and metastasis-directed therapy upon investigator's discretion and be followed-up for up to 2 years.

Progression free survival (PFS) and overall survival (OS) will be collected during this study.

For the subjects with unresectable primary tumour after NHT, PFS and OS will also be collected in the follow-up for up to 2 years after 24 weeks of CAB.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 9
• Est. completion date: November 9, 2022
• Est. primary completion date: November 9, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. Diagnosed within the past 12 months with T2DM according to 1999 WHO criteria

2. Men and women aged at least 18 years at screening.

3. Either not received oral anti-diabetic drugs or had been on short-term (1 month) treatment that had been discontinued 3 months before enrolment.

4. HbA1c = 7.5% and = 10.5% at screening and HbA1c = 7.0% and = 10.5% at pre-randomization visit.

5. FPG = 13.3 mmol/L (= 240 mg/dL) .

6. BMI=18.5 kg/m2 and = 45.0 kg/m2 .

7. C-peptide =0.33nmol/L(=1.0 ng/mL).

8. Able and willing to provide written informed consent and to comply with the study.

Exclusion Criteria:

1. Women who are pregnant, intending to become pregnant during the study period, currently lactating females, or women of child-bearing potential not using highly effective, medically approved birth control methods.

2. Diagnosis or history of:

1. Acute metabolic diabetic complications such as ketoacidosis or hyperglycemic hyperosmolar state

2. Diabetes insipidus.

3. Requirement for insulin therapy. Symptoms of poorly controlled diabetes, including but not limited to, marked polyuria and polydipsia with >10% weight loss during the 3 months before enrollment.

4. Triglycerides (fasting) > 9.3 mmol/L (> 800 mg/dL).

5. Patients with clinically apparent hepatobiliary disease, including but not limited to chronic active hepatitis and/or severe hepatic insufficiency. ALT or AST > 3x upper limit of normal (ULN), or serum total bilirubin (TB) >34.2 µmol/L (>2 mg/dL).

6. Patiens with following renal disease history or renal disease related features:

1. History of unstable or rapidly progressing renal disease;

2. Patients with moderate /severe renal impairment or end-stage renal disease (eGFR< 60 mL/min/1.73 m2)

3. Urinary albumin: creatinine ratio >1800 mg/g;

4. Serum creatinine (Cr) =133 µmol/L (=1.50 mg/dL) for male subjects; Serum Cr=124 µmol/L (=1.40 mg/dL) for female subjects;

5. Conditions of congenital renal glycosuria.

7. Severe uncontrolled hypertension defined as SBP =180 mmHg and/or BP =110 mmHg;Patients with SBP < 95mmHg.

8. Any of the following cardiovascular diseases within 6 months of the enrollment visit:

1. Myocardial infarction;

2. Cardiac surgery or revascularization (coronary artery bypass graft/percutaneous transluminal coronary angioplasty);

3. Unstable angina;

4. Congestive heart failure New York Heart Association Class III or IV;

5. Transient ischemic attack or significant cerebrovascular disease.

9. History of gastrointestinal disease or surgery including Roemheld Syndrome, severe hernia, intestinal obstruction, intestinal ulcer, gastroenterostomy, enterectomy, bariatric surgery or lap-band procedure.

10. Malignancy within 5 years of the enrollment visit (with the exception of treated basal cell or treated squamous cell carcinoma).

11. Known immunocompromised status, including but not limited to, individuals who had undergone organ transplantation or acquired immunodeficiency syndrome (AIDS).

12. Any subject who, in the judgment of the investigator, was at risk for dehydration or volume depletion that might affect the interpretation of efficacy or safety data.

13. History of bone fracture secondary to diagnosed severe osteoporosis.

14. Currently unstable or serious cardiovascular, renal, hepatic, hematologic, oncologic, endocrine, psychiatric, or rheumatic diseases as judged by the Investigator.

15. Replacement or chronic systemic corticosteroid therapy, defined as any dose of systemic corticosteroid taken for >4 weeks within 3 months before enrollment visit.

16. Administration of sibutramine, phentermine, orlistat, rimonabant, benzphetamine, diethylpropion, methamphetamine, or phendimetrazine within 30 days of enrollment visit.

17. Any subject who was currently abusing alcohol or other drugs or had done so within the last 6 months

18. Donation of blood or blood products, blood transfusion, or participation in a clinical study requiring withdrawal of >400 mL of blood during the 6 weeks before the enrollment visit

19. History of hypersensitivity reaction to dapagliflozin or acarbose. Allergies or contraindication to the contents of dapagliflozin tablets or acarbose tablests.

20. Previous participation in a clinical trial with dapagliflozin.

21. Administration of any other investigational drug within 30 days of planned enrollment to this study, or within 5 half-life periods of other investigational drugs.

22. Subject is, in the judgment of the Investigator, unlikely to comply with the protocol or has any severe concurrent medical or psychological condition that may affect the interpretation of efficacy or safety data.

Related Conditions & MeSH terms

• Advanced Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• Zoladex and Casodex
The eligible subjects will receive Casodex 50 mg orally per day in combination with Zoladex 10.8 mg implant subcutaneously as neoadjuvant therapy per 12 weeks for up to 24 weeks.

Locations

Country	Name	City	State
China	Research Site	Beijing
China	Research Site	Changsha
China	Research Site	Changsha
China	Research Site	Chengdu
China	Research Site	Guangzhou
China	Research Site	Guangzhou
China	Research Site	Hangzhou
China	Research Site	Hangzhou
China	Research Site	Hefei
China	Research Site	Shanghai
China	Research Site	Shenyang
China	Research Site	Shijiazhuang
China	Research Site	Urumqi
China	Research Site	Xi'an
China	Research Site	Zhengzhou

Sponsors (1)

Lead Sponsor	Collaborator
AstraZeneca

Country where clinical trial is conducted

China, 

References & Publications (1)

1. Montironi R, Schulman CC. Pathological changes in prostate lesions after androgen manipulation. J Clin Pathol 1998; 51:5-12. 2. Witjes WP, Schulman CC, Debruyne FM. Preliminary results of a prospective randomized study comparing radical prostatectomy v

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Resectability rate for primary tumour (the resectability will be assessed by central review using a digital rectal examination and confirmed by CT or MRI)	To assess the efficacy by resectability rate of neoadjuvant hormone therapy (NHT) in subjects with advanced prostate cancer	at 24 week
Secondary	Radical prostatectomy rate	Which will be derived using the number of patient who will conduct the radical prostatectomy at 24 week.	From baseline to 24 week
Secondary	The mean PSA by the end of NHT	which will be derived using the value of mean PSA by the end of NHT	From baseline to 24 week
Secondary	Percentage of positive surgical margin for primary tumour	Which will be derived using the number of positive surgical margin at 24 week	From baseline to 24 week
Secondary	Incidence of seminal vesicle invasion	Which will be derived using the value of incidence of seminal vesicle invasion at 24 week	From baseline to 24 week.
Secondary	Percentage of pathological downstaging	Which will be derived using the number of pathological downstaging at 24 week.	From baseline to 24 week
Secondary	surgical-related variables at 12 weeks, potent rates in erectile function at 12 weeks after surgery	Which will be derived using the value of observe surgical-related variables and complications at week 36	From 24 week to 36 week
Secondary	PFS	Which will be derived using the number of PFS at the end of study	From baseline to the end of study
Secondary	AEs/SAEs	To evaluate the safety of NHT using goserelin and bicalutamide	From baseline to 28 week
Secondary	PSA change from baseline	Which will be derived using the value of PSA at the baseline.	From baseline to 24 week
Secondary	Involvement of bilateral pelvic lymph nodes	Which will be derived using the value of involvement of bilateral pelvic lymph nodes at 24 week.	From baseline to 24 week
Secondary	OS	Which will be derived using the number of OS at the end of study.	From baseline to the end of study